Cardiac asthma: New insights into an old disease

Expert Review of Respiratory Medicine

Volumn 6, Issue 6, 2012, Pages 705-714

  Tanabe, Tsuyoshi ^a   Rozycki, Henry J ^a   Kanoh, Soichiro ^a   Rubin, Bruce K ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

airflow obstruction; airway inflammation; heart failure; pulmonary edema; remodeling heart; squamous metaplasia; systemic inflammation; TGF

Indexed keywords

BRONCHODILATING AGENT; CORTICOSTEROID; DIURETIC AGENT;

AIRWAY OBSTRUCTION; ASTHMA; CONGESTIVE HEART FAILURE; COUGHING; DYSPNEA; HEART ASTHMA; HEART DISEASE; HUMAN; LUNG CONGESTION; LUNG EDEMA; ORTHOPNEA; PATHOPHYSIOLOGY; REVIEW; WHEEZING;

EID: 84871014192     PISSN: 17476348     EISSN: 17476356     Source Type: Journal    
DOI: 10.1586/ers.12.67     Document Type: Review

References (108)

1. Hope J. A Treatise On The Diseases Of The Heart And Great Vessels. Third edition. Lea and Blanchard, PA, USA, 466-471 (1839).
2. Osler W. Lectures On Angina And Pectoris And Allied States. D Appleton and Company, NY, USA, 52 (1897).
3. Kahn MH. Cardiac Asthma. Bull. N. Y. Acad. Med. 3(11), 632-642 (1927).
4. Lombardo TA, Harrison TR. Cardiac asthma. Circulation 4(6), 920-929 (1951).
5. Burr ML, Charles TJ, Roy K, Seaton A. Asthma in the elderly: an epidemiological survey. Br. Med. J. 1(6170), 1041-1044 (1979). (Pubitemid 9148521)
6. Evans R 3rd, Mullally DI, Wilson RW et al. National trends in the morbidity and mortality of asthma in the US. Prevalence, hospitalization and death from asthma over two decades: 1965-1984. Chest 91(Suppl. 6), 65S-74S (1987).
7. Enright PL, McClelland RL, Newman AB, Gottlieb DJ, Lebowitz MD. Underdiagnosis and undertreatment of asthma in the elderly. Cardiovascular Health Study Research Group. Chest 116(3), 603-613 (1999). (Pubitemid 29428473)
8. Jorge S, Becquemin MH, Delerme S et al. Cardiac asthma in elderly patients: incidence, clinical presentation and outcome. BMC Cardiovasc. Disord. 7, 16 (2007).
9. Auld PA, Rudolph AM, Golinko RJ. Factors affecting bronchial collateral flow in the dog. Am. J. Physiol. 198, 1166-1170 (1960).
10. Baier H, Onorato D, Barker J, Wanner A. Tracheal mucosal edema in hydrostatic pulmonary edema. J. Appl. Physiol. 77(1), 352-356 (1994). (Pubitemid 24226155)
11. Ceridon M, Wanner A, Johnson BD. Does the bronchial circulation contribute to congestion in heart failure? Med. Hypotheses 73(3), 414-419 (2009).
12. Agostoni PG, Doria E, Bortone F, Antona C, Moruzzi P. Systemic to pulmonary bronchial blood flow in heart failure. Chest 107(5), 1247-1252 (1995).
13. Wagner EM, Mitzner WA. Effect of left atrial pressure on bronchial vascular hemodynamics. J. Appl. Physiol. 69(3), 837-842 (1990). (Pubitemid 20338679)
14. McCullagh A, Rosenthal M, Wanner A, Hurtado A, Padley S, Bush A. The bronchial circulation -worth a closer look: a review of the relationship between the bronchial vasculature and airway inflammation. Pediatr. Pulmonol. 45(1), 1-13 (2010).
15. Paredi P, Barnes PJ. The airway vasculature: recent advances and clinical implications. Thorax 64(5), 444-450 (2009).
16. Stothert JC Jr, Basadre JO, Gbaanador GB, Flynn JT, Traber L, Traber D. Bronchial blood flow during changes in inhaled oxygen and carbon dioxide concentrations in conscious sheep. Circ. Shock 36(2), 120-126 (1992).
17. Snyder EM, Beck KC, Turner ST, Hoffman EA, Joyner MJ, Johnson BD. Genetic variation of the β2-adrenergic receptor is associated with differences in lung fluid accumulation in humans. J. Appl. Physiol. 102(6), 2172-2178 (2007). (Pubitemid 47082405)
18. Pellegrino R, Dellaca R, Macklem PT et al. Effects of rapid saline infusion on lung mechanics and airway responsiveness in humans. J. Appl. Physiol. 95(2), 728-734 (2003). (Pubitemid 36944298)
19. King LS, Nielsen S, Agre P, Brown RH. Decreased pulmonary vascular permeability in aquaporin-1-null humans. Proc. Natl Acad. Sci. USA 99(2), 1059-1063 (2002). (Pubitemid 34106635)
20. Nishimura Y, Maeda H, Hashimoto A, Tanaka K, Yokoyama M. Effect of posture on bronchial reactivity to inhaled methacholine in patients with mitral valve stenosis. Chest 106(5), 1391-1395 (1994). (Pubitemid 24346097)
21. Boni E, Bezzi M, Carminati L, Corda L, Grassi V, Tantucci C. Expiratory flow limitation is associated with orthopnea and reversed by vasodilators and diuretics in left heart failure. Chest 128(2), 1050-1057 (2005). (Pubitemid 41140548)
22. Torchio R, Gulotta C, Greco-Lucchina P et al. Orthopnea and tidal expiratory flow limitation in chronic heart failure. Chest 130(2), 472-479 (2006). (Pubitemid 44267015)
23. Chiu KL, Ryan CM, Shiota S et al. Fluid shift by lower body positive pressure increases pharyngeal resistance in healthy subjects. Am. J. Respir. Crit. Care Med. 174(12), 1378-1383 (2006). (Pubitemid 44913040)
24. Haworth SG, Hall SM, Panja M, Patel M. Peripheral pulmonary vascular and airway abnormalities in adolescents with rheumatic mitral stenosis. Int. J. Cardiol. 18(3), 405-416 (1988). (Pubitemid 18045283)
25. Kee K, Naughton MT. Heart failure and the lung. Circ. J. 74(12), 2507-2516 (2010).
26. Parker F, Weiss S. The nature and significance of the structural changes in the lungs in mitral stenosis. Am. J. Pathol. 12(5), 573-598.15 (1936).
27. Araya J, Cambier S, Markovics JA et al. Squamous metaplasia amplifies pathologic epithelial-mesenchymal interactions in COPD patients. J. Clin. Invest. 117(11), 3551-3562 (2007). (Pubitemid 350097010)
28. Takizawa H, Tanaka M, Takami K et al. Increased expression of transforming growth factor-β1 in small airway epithelium from tobacco smokers and patients with chronic obstructive pulmonary disease (COPD). Am. J. Respir. Crit. Care Med. 163(6), 1476-1483 (2001). (Pubitemid 32506619)
29. Edgley AJ, Krum H, Kelly DJ. Targeting fibrosis for the treatment of heart failure: a role for transforming growth factor-β. Cardiovasc. Ther. 30(1), e30-e40 (2012).
30. Porter KE, Turner NA. Cardiac fibroblasts: at the heart of myocardial remodeling. Pharmacol. Ther. 123(2), 255-278 (2009).
31. Bujak M, Frangogiannis NG. The role of TGF-β signaling in myocardial infarction and cardiac remodeling. Cardiovasc. Res. 74(2), 184-195 (2007). (Pubitemid 46517504)
32. Halwani R, Al-Muhsen S, Al-Jahdali H, Hamid Q. Role of transforming growth factor-β in airway remodeling in asthma. Am. J. Respir. Cell Mol. Biol. 44(2), 127-133 (2011).
33. Yue P, Massie BM, Simpson PC, Long CS. Cytokine expression increases in nonmyocytes from rats with postinfarction heart failure. Am. J. Physiol. 275(1 Pt 2), H250-H258 (1998).
34. Zhao L, Eghbali-Webb M. Release of pro-and anti-angiogenic factors by human cardiac fibroblasts: effects on DNA synthesis and protection under hypoxia in human endothelial cells. Biochim. Biophys. Acta 1538(2-3), 273-282 (2001). (Pubitemid 32402250)
35. LaFramboise WA, Scalise D, Stoodley P et al. Cardiac fibroblasts influence cardiomyocyte phenotype in vitro. Am. J. Physiol. Cell Physiol. 292(5), C1799-C1808 (2007). (Pubitemid 47080551)
36. Rosenkranz S. TGF-β1 and angiotensin networking in cardiac remodeling. Cardiovasc. Res. 63(3), 423-432 (2004). (Pubitemid 38970186)
37. Almendral JL, Shick V, Rosendorff C, Atlas SA. Association between transforming growth factor-β(1) and left ventricular mass and diameter in hypertensive patients. J. Am. Soc. Hypertens. 4(3), 135-141 (2010).
38. Tanabe T, Kanoh S, Moskowitz WB, Rubin BK. Cardiac asthma: TGF-β from the failing heart leads to squamous metaplasia in human airway cells and in the murine lung. Chest doi:10.1378/ chest.11-1710 (2012) (Epub ahead of print).
39. McMillan SJ, Xanthou G, Lloyd CM. Manipulation of allergen-induced airway remodeling by treatment with anti-TGF-β antibody: effect on the Smad signaling pathway. J. Immunol. 174(9), 5774-5780 (2005). (Pubitemid 40593221)
40. Lizak MK, Zakliczynski M, Jarosz A, Zembala M. The influence of chronic heart failure on pulmonary function tests in patients undergoing orthotopic heart transplantation. Transplant. Proc. 41(8), 3194-3197 (2009).
41. Cabanes LR, Weber SN, Matran R et al. Bronchial hyperresponsiveness to methacholine in patients with impaired left ventricular function. N. Engl. J. Med. 320(20), 1317-1322 (1989). (Pubitemid 19140407)
42. Pison C, Malo JL, Rouleau JL, Chalaoui J, Ghezzo H, Malo J. Bronchial hyperresponsiveness to inhaled methacholine in subjects with chronic left heart failure at a time of exacerbation and after increasing diuretic therapy. Chest 96(2), 230-235 (1989). (Pubitemid 19199526)
43. Nishimura Y, Maeda H, Yokoyama M, Fukuzaki H. Bronchial hyperreactivity in patients with mitral valve disease. Chest 98(5), 1085-1090 (1990). (Pubitemid 20381266)
44. Nishimura Y, Maeda H, Hashimoto A, Tanaka K, Yokoyama M. Relationship between bronchial hyperreactivity and the symptoms of cardiac asthma in patients with non-valvular left ventricular failure. Jpn. Circ. J. 60(12), 933-939 (1996).
45. Saitoh Y, Sasaki F, Ishizaki T, Miyabo S, Kanamori K, Mifune J. Bronchial hyperresponsiveness to acetylcholine in patients with vasospastic angina pectoris. Chest 105(2), 364-367 (1994). (Pubitemid 24066699)
46. Nishimura Y, Yu Y, Kotani Y et al. Bronchial hyperresponsiveness and exhaled nitric oxide in patients with cardiac disease. Respiration. 68(1), 41-45 (2001). (Pubitemid 32172953)
47. Hasking GJ, Esler MD, Jennings GL, Burton D, Johns JA, Korner PI. Norepinephrine spillover to plasma in patients with congestive heart failure: evidence of increased overall and cardiorenal sympathetic nervous activity. Circulation 73(4), 615-621 (1986). (Pubitemid 16081418)
48. Snashall PD, Chung KF. Airway obstruction and bronchial hyperresponsiveness in left ventricular failure and mitral stenosis. Am. Rev. Respir. Dis. 144(4), 945-956 (1991).
49. Borst MM, Beuthien W, Schwencke C et al. Desensitization of the pulmonary adenyl cyclase system: a cause of airway hyperresponsiveness in congestive heart failure? J. Am Coll Cardiol. 34(3), 848-856 (1999). (Pubitemid 29436193)
50. Levin ER. Endothelins. N. Engl. J. Med. 333(6), 356-363 (1995).
51. Mascarenhas J, Azevedo A, Bettencourt P. Coexisting chronic obstructive pulmonary disease and heart failure: implications for treatment, course and mortality. Curr. Opin. Pulm. Med. 16(2), 106-111 (2010).
52. Macchia A, Rodriguez Moncalvo JJ, Kleinert M et al. Unrecognised ventricular dysfunction in COPD. Eur. Respir. J. 39(1), 51-58 (2012).
53. Yanbaeva DG, Dentener MA, Creutzberg EC, Wesseling G, Wouters EF. Systemic effects of smoking. Chest 131(5), 1557-1566 (2007). (Pubitemid 46762366)
54. Nanjo S, Yoshikawa K, Harada M et al. Correlation between left ventricular diastolic function and ejection fraction in dilated cardiomyopathy using magnetic resonance imaging with late gadolinium enhancement. Circ. J. 73(10), 1939-1944 (2009).
55. Szollosi I, Thompson BR, Krum H, Kaye DM, Naughton MT. Impaired pulmonary diffusing capacity and hypoxia in heart failure correlates with central sleep apnea severity. Chest 134(1), 67-72 (2008). (Pubitemid 352008765)
56. Yumino D, Redolfi S, Ruttanaumpawan P et al. Nocturnal rostral fluid shift: a unifying concept for the pathogenesis of obstructive and central sleep apnea in men with heart failure. Circulation 121(14), 1598-1605 (2010).
57. ten Brinke A, Sterk PJ, Masclee AA et al. Risk factors of frequent exacerbations in difficult-to-treat asthma. Eur. Respir. J. 26(5), 812-818 (2005). (Pubitemid 41632037)
58. Alkhalil M, Schulman E, Getsy J. Obstructive sleep apnea syndrome and asthma: what are the links? J. Clin. Sleep Med. 5(1), 71-78 (2009).
59. Boushey HA, Holtzman MJ, Sheller JR, Nadel JA. Bronchial hyperreactivity. Am. Rev. Respir. Dis. 121(2), 389-413 (1980). (Pubitemid 10095236)
60. Morrison JF, Pearson SB. The parasympathetic nervous system and the diurnal variation of lung mechanics in asthma. Respir. Med. 85(4), 285-289 (1991).
61. Coe CI, Barnes PJ. Reduction of nocturnal asthma by an inhaled anticholinergic drug. Chest 90(4), 485-488 (1986). (Pubitemid 17191555)
62. Teramoto S, Yamamoto H, Ouchi Y. Increased C-reactive protein and increased plasma interleukin-6 may synergistically affect the progression of coronary atherosclerosis in obstructive sleep apnea syndrome. Circulation 107(5), E40-E40 (2003).
63. Dyugovskaya L, Lavie P, Lavie L. Increased adhesion molecules expression and production of reactive oxygen species in leukocytes of sleep apnea patients. Am. J. Respir. Crit. Care Med. 165(7), 934-939 (2002). (Pubitemid 34774660)
64. Vgontzas AN, Papanicolaou DA, Bixler EO, Kales A, Tyson K, Chrousos GP. Elevation of plasma cytokines in disorders of excessive daytime sleepiness: role of sleep disturbance and obesity. J. Clin. Endocrinol. Metab. 82(5), 1313-1316 (1997). (Pubitemid 27200394)
65. Yokoe T, Minoguchi K, Matsuo H et al. Elevated levels of C-reactive protein and interleukin-6 in patients with obstructive sleep apnea syndrome are decreased by nasal continuous positive airway pressure. Circulation 107(8), 1129-1134 (2003). (Pubitemid 36297204)
66. Ohga E, Nagase T, Tomita T et al. Increased levels of circulating ICAM-1, VCAM-1, and L-selectin in obstructive sleep apnea syndrome. J. Appl. Physiol. 87(1), 10-14 (1999). (Pubitemid 29330658)
67. Shahar E, Whitney CW, Redline S et al. Sleep-disordered breathing and cardiovascular disease: cross-sectional results of the Sleep Heart Health Study. Am. J. Respir. Crit. Care Med. 163(1), 19-25 (2001). (Pubitemid 32095247)
68. Parker JD, Brooks D, Kozar LF et al. Acute and chronic effects of airway obstruction on canine left ventricular performance. Am. J. Respir. Crit. Care Med. 160(6), 1888-1896 (1999). (Pubitemid 30004692)
69. Calverley PM, Scott S. Is airway inflammation in chronic obstructive pulmonary disease (COPD) a risk factor for cardiovascular events? COPD 3(4), 233-242 (2006). (Pubitemid 44949063)
70. Higgins MW, Enright PL, Kronmal RA, Schenker MB, Anton-Culver H, Lyles M. Smoking and lung function in elderly men and women. The Cardiovascular Health Study. JAMA 269(21), 2741-2748 (1993). (Pubitemid 23154247)
71. Enright PL, Kronmal RA, Higgins MW, Schenker MB, Haponik EF. Prevalence and correlates of respiratory symptoms and disease in the elderly. Cardiovascular Health Study. Chest 106(3), 827-834 (1994). (Pubitemid 24278891)
72. St-Laurent J, Bergeron C, Pagé N, Couture C, Laviolette M, Boulet LP. Influence of smoking on airway inflammation and remodelling in asthma. Clin. Exp. Allergy 38(10), 1582-1589 (2008).
73. Yndestad A, Damås JK, Oie E, Ueland T, Gullestad L, Aukrust P. Systemic inflammation in heart failure -the whys and wherefores. Heart Fail. Rev. 11(1), 83-92 (2006). (Pubitemid 43986210)
74. Pierce GL, Schofield RS, Casey DP, Hamlin SA, Hill JA, Braith RW. Effects of exercise training on forearm and calf vasodilation and proinflammatory markers in recent heart transplant recipients: a pilot study. Eur. J. Cardiovasc. Prev. Rehabil. 15(1), 10-18 (2008). (Pubitemid 351263249)
75. Charalambous BM, Stephens RC, Feavers IM, Montgomery HE. Role of bacterial endotoxin in chronic heart failure: the gut of the matter. Shock 28(1), 15-23 (2007). (Pubitemid 46956457)
76. Chua TP, Lalloo UG, Worsdell MY, Kharitonov S, Chung KF, Coats AJ. Airway and cough responsiveness and exhaled nitric oxide in non-smoking patients with stable chronic heart failure. Heart 76(2), 144-149 (1996). (Pubitemid 26258741)
77. Morrison JF, Pearson SB, Dean HG. Parasympathetic nervous system in nocturnal asthma. Br. Med. J. (Clin. Res. Ed.) 296(6634), 1427-1429 (1988).
78. Hunt SA, Abraham WT, Chin MH et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 119(14), e391-e479 (2009).
79. Felker GM, Lee KL, Bull DA et al.; NHLBI Heart Failure Clinical Research Network. Diuretic strategies in patients with acute decompensated heart failure. N. Engl. J. Med. 364(9), 797-805 (2011).
80. Spyratos DG, Glattki GP, Sichletidis LT, Patakas D. Assessment of respiratory mechanics by impulse oscillometry in orthopneic patients with acute left ventricular failure. Heart Lung 40(2), 97-104 (2011).
81. Hunt SA; American College of Cardiology; American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J. Am. Coll. Cardiol. 46(6), e1-82 (2005).
82. Salpeter SR, Ormiston TM, Salpeter EE, Poole PJ, Cates CJ. Cardioselective β-blockers for chronic obstructive pulmonary disease: a meta-analysis. Respir. Med. 97(10), 1094-1101 (2003). (Pubitemid 37185112)
83. Hawkins NM, MacDonald MR, Petrie MC et al. Bisoprolol in patients with heart failure and moderate to severe chronic obstructive pulmonary disease: a randomized controlled trial. Eur. J. Heart Fail. 11(7), 684-690 (2009).
84. Moore DP, Weston A, Hughes JM, Oakley CM, Cleland JG. Bronchial hyperresponsiveness in heart failure. N. Engl. J. Med. 328(19), 1424-1425 (1993).
85. Brunnée T, Graf K, Kastens B, Fleck E, Kunkel G. Bronchial hyperreactivity in patients with moderate pulmonary circulation overload. Chest 103(5), 1477-1481 (1993). (Pubitemid 23145606)
86. Faggiano P. Abnormalities of pulmonary function in congestive heart failure. Int. J. Cardiol. 44(1), 1-8 (1994). (Pubitemid 24110042)
87. Cazzola M, Matera MG, Donner CF. Inhaled β2-adrenoceptor agonists: cardiovascular safety in patients with obstructive lung disease. Drugs 65(12), 1595-1610 (2005). (Pubitemid 41138983)
88. Maak CA, Tabas JA, McClintock DE. Should acute treatment with inhaled β agonists be withheld from patients with dyspnea who may have heart failure? J. Emerg. Med. 40(2), 135-145 (2011).
89. Kindman LA, Vagelos RH, Willson K, Prikazky L, Fowler M. Abnormalities of pulmonary function in patients with congestive heart failure, and reversal with ipratropium bromide. Am. J. Cardiol. 73(4), 258-262 (1994). (Pubitemid 24050079)
90. Rolla G, Bucca C, Brussino L, Gallo W, Malara D. Bronchodilating effect of ipratropium bromide in heart failure. Eur. Respir. J. 6(10), 1492-1495 (1993). (Pubitemid 24007884)
91. Mutlu GM, Sznajder JI. Mechanisms of pulmonary edema clearance. Am. J. Physiol. Lung Cell Mol. Physiol. 289(5), L685-L695 (2005). (Pubitemid 41504397)
92. Sakuma T, Folkesson HG, Suzuki S, Okaniwa G, Fujimura S, Matthay MA. β-adrenergic agonist stimulated alveolar fluid clearance in ex vivo human and rat lungs. Am. J. Respir. Crit. Care Med. 155(2), 506-512 (1997). (Pubitemid 27085793)
93. Minakata Y, Suzuki S, Grygorczyk C, Dagenais A, Berthiaume Y. Impact of β-adrenergic agonist on Na+ channel and Na+-K+-ATPase expression in alveolar type II cells. Am. J. Physiol. 275(2 Pt 1), L414-L422 (1998).
94. Licker M, Tschopp JM, Robert J, Frey JG, Diaper J, Ellenberger C. Aerosolized salbutamol accelerates the resolution of pulmonary edema after lung resection. Chest 133(4), 845-852 (2008). (Pubitemid 351536857)
95. El-Menyar AA. Cytokines and myocardial dysfunction: state of the art. J. Card. Fail. 14(1), 61-74 (2008). (Pubitemid 351146639)
96. Bona RD, Liuzzo G, Pedicino D, Crea F. Anti-inflammatory treatment of acute coronary syndromes. Curr. Pharm. Des. 17(37), 4172-4189 (2011).
97. MacGowan GA, McNamara DM. New molecular insights into heart failure and cardiomyopathy: potential strategies and therapies. Ir. J. Med. Sci. 171(2), 99-104 (2002).
98. Walsh GM. Novel cytokine-directed therapies for asthma. Discov. Med. 11(59), 283-291 (2011).
99. Leckie MJ, ten Brinke A, Khan J et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 356(9248), 2144-2148 (2000).
100. Flood-Page PT, Menzies-Gow AN, Kay AB, Robinson DS. Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am. J. Respir. Crit. Care Med. 167(2), 199-204 (2003). (Pubitemid 36076080)
101. Flood-Page P, Swenson C, Faiferman I et al.; International Mepolizumab Study Group. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am. J. Respir. Crit. Care Med. 176(11), 1062-1071 (2007). (Pubitemid 350223751)
102. Wenzel S, Wilbraham D, Fuller R, Getz EB, Longphre M. Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two Phase 2a studies. Lancet 370(9596), 1422-1431 (2007). (Pubitemid 47576168)
103. Corren J, Busse W, Meltzer EO et al. A randomized, controlled, Phase 2 study of AMG 317, an IL-4Ralpha antagonist, in patients with asthma. Am. J. Respir. Crit. Care Med. 181(8), 788-796 (2010).
104. Ulrik CS, Carlsen J, Arendrup H, Aldershvile J. Pulmonary function in chronic heart failure. Changes after heart transplantation. Scand. Cardiovasc. J. 33(3), 131-136 (1999). (Pubitemid 29374004)
105. Habedank D, Ewert R, Hummel M, Wensel R, Hetzer R, Anker SD. Changes in exercise capacity, ventilation, and body weight following heart transplantation. Eur. J. Heart Fail. 9(3), 310-316 (2007). (Pubitemid 46350723)
106. Al-Rawas OA, Carter R, Stevenson RD, Naik SK, Wheatley DJ. Exercise intolerance following heart transplantation: the role of pulmonary diffusing capacity impairment. Chest 118(6), 1661-1670 (2000). (Pubitemid 32001793)
107. Ravenscraft SA, Gross CR, Kubo SH et al. Pulmonary function after successful heart transplantation. One year follow-up. Chest 103(1), 54-58 (1993). (Pubitemid 23027232)
108. Morrison JF, Higenbottam TW, Hathaway TJ, Clelland C, Scott JP, Wallwork J. Diurnal variation in FEV1 after heart-lung transplantation. Eur. Respir. J. 5(7), 834-840 (1992).